HeartScience MyoVista® high sensitivity ECG (hsECG™) Cardiac Testing Device is a breakthrough in the early detection of cardiac dysfunction*. MyoVista hsECG is designed to fill a diagnostic gap identifying both asymptomatic and symptomatic patients at elevated cardiac risk of an adverse event. It’s patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on cardiac performance and energy during repolarization, rather than conventional voltage-based ECG information, and provide valuable new data to assist in identifying repolarization abnormalities. MyoVista hsECG technology addresses a major clinical, technical and economic need in testing of cardiac dysfunction with an easy to adopt, easy to interpret, low-cost and non-invasive solution that does not require any change in conventional resting 12-lead ECG clinical workflow.

• MyoVista technology detects cardiac dysfunction in the diastolic phase.